These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26357866)

  • 1. Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus.
    Khan S; Khan S; Panda BP; Akhtar M; Najmi AK
    Expert Opin Ther Targets; 2015; 19(12):1607-16. PubMed ID: 26357866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats.
    Refaat R; Sakr A; Salama M; El Sarha A
    Drug Dev Res; 2016 Sep; 77(6):300-9. PubMed ID: 27520857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.
    Khan S; Khan S; Imran M; Pillai KK; Akhtar M; Najmi AK
    Expert Opin Ther Targets; 2013 Jun; 17(6):627-39. PubMed ID: 23356568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
    Sharma AK; Kanawat DS; Mishra A; Dhakad PK; Sharma P; Srivastava V; Joshi S; Joshi M; Raikwar SK; Kurmi MK; Srinivasan BP
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.
    Eom YS; Gwon AR; Kwak KM; Kim JY; Yu SH; Lee S; Kim YS; Park IB; Kim KW; Lee K; Kim BJ
    PLoS One; 2016; 11(12):e0168569. PubMed ID: 27997588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats.
    Abdelhamid AM; Abdelaziz RR; Salem HAA
    Can J Physiol Pharmacol; 2018 Aug; 96(8):710-718. PubMed ID: 29510081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats.
    El Batsh MM; El Batch MM; Shafik NM; Younos IH
    Eur J Pharmacol; 2015 Dec; 769():297-305. PubMed ID: 26607467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trigonelline and vildagliptin antidiabetic effect: improvement of insulin signalling pathway.
    Aldakinah AA; Al-Shorbagy MY; Abdallah DM; El-Abhar HS
    J Pharm Pharmacol; 2017 Jul; 69(7):856-864. PubMed ID: 28271502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological sheet. Vildagliptin, oral administration (GALVUS)].
    J Pharm Belg; 2009 Jun; (2):64-6. PubMed ID: 19739530
    [No Abstract]   [Full Text] [Related]  

  • 11. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
    Akarte AS; Srinivasan BP; Gandhi S
    J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats.
    Zhang Q; Xiao X; Li M; Yu M; Ping F; Zheng J; Wang T; Wang X
    PLoS One; 2017; 12(10):e0184735. PubMed ID: 29036231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
    Abdelsalam RM; Safar MM
    J Neurochem; 2015 Jun; 133(5):700-7. PubMed ID: 25752913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
    Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
    Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
    Akarte AS; Srinivasan BP; Gandhi S
    Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post-hoc subanalysis of the Belgian data.
    Hoste J; Daci E; Mathieu C
    Acta Clin Belg; 2014 Jun; 69(3):171-6. PubMed ID: 24820924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin induces β-cell neogenesis and improves the lipid profile in a later phase of type 1 diabetes.
    de Amorim Miranda PH; Monteiro OM; Rossoni JV; Silva ME; de Lima WG; Costa DC
    Curr Pharm Biotechnol; 2015; 16(1):60-5. PubMed ID: 25395211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice.
    Mookkan J; De S; Shetty P; Kulkarni NM; Devisingh V; Jaji MS; Lakshmi VP; Chaudhary S; Kulathingal J; Rajesh NB; Narayanan S
    Indian J Pharmacol; 2014; 46(1):46-50. PubMed ID: 24550584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
    Ahrén B; Foley JE; Bosi E
    Diabetes Obes Metab; 2011 Mar; 13(3):193-203. PubMed ID: 21205107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
    Roy S; Khanna V; Mittra S; Dhar A; Singh S; Mahajan DC; Priyadarsiny P; Davis JA; Sattigeri J; Saini KS; Bansal VS
    Life Sci; 2007 Jun; 81(1):72-9. PubMed ID: 17532347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.